Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Ironwood Pharmaceuti (IRWD)

Ironwood Pharmaceuti (IRWD)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 563,299
  • Shares Outstanding, K 160,028
  • Annual Sales, $ 442,740 K
  • Annual Income, $ -1,002 M
  • EBIT $ 99 M
  • EBITDA $ 101 M
  • 60-Month Beta 0.47
  • Price/Sales 1.38
  • Price/Cash Flow N/A
  • Price/Book N/A

Options Overview Details

View History
  • Implied Volatility 97.84% ( -161.91%)
  • Historical Volatility 74.73%
  • IV Percentile 71%
  • IV Rank 26.11%
  • IV High 297.29% on 11/15/24
  • IV Low 27.36% on 06/10/24
  • Put/Call Vol Ratio 0.05
  • Today's Volume 40
  • Volume Avg (30-Day) 35
  • Put/Call OI Ratio 0.10
  • Today's Open Interest 1,575
  • Open Int (30-Day) 3,460

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate 0.08
  • Number of Estimates 3
  • High Estimate 0.09
  • Low Estimate 0.07
  • Prior Year 0.00
  • Growth Rate Est. (year over year) N/A

Price Performance

See More
Period Period Low Period High Performance
1-Month
3.32 +0.57%
on 11/21/24
5.07 -34.14%
on 11/11/24
-0.85 (-20.31%)
since 10/21/24
3-Month
3.32 +0.57%
on 11/21/24
5.20 -35.85%
on 08/29/24
-1.66 (-33.22%)
since 08/21/24
52-Week
3.32 +0.57%
on 11/21/24
15.70 -78.73%
on 02/14/24
-6.03 (-64.37%)
since 11/21/23

Most Recent Stories

More News
Ironwood: Q3 Earnings Snapshot

Ironwood: Q3 Earnings Snapshot

IRWD : 3.35 (-4.83%)
Implied Volatility Surging for Ironwood (IRWD) Stock Options

Investors in Ironwood Pharmaceuticals, Inc. IRWD need to pay close attention to the stock based on moves in the options market lately. That is because the Oct. 18, 2024 $2.50 Put had some of the highest...

IRWD : 3.35 (-4.83%)
Ironwood: Q2 Earnings Snapshot

Ironwood: Q2 Earnings Snapshot

IRWD : 3.35 (-4.83%)
Ironwood: Q1 Earnings Snapshot

Ironwood: Q1 Earnings Snapshot

IRWD : 3.35 (-4.83%)
Ironwood: Q4 Earnings Snapshot

Ironwood: Q4 Earnings Snapshot

IRWD : 3.35 (-4.83%)
Chart of the Day: Ironwood Pharma - Gastrointestinal Products

The Chart of the Day belongs to the gastrointestinal pharmaceutical products company Ironwood Pharmaceutical (IRWD) I found the stock by using Barchart's powerful screening functions to find stocks...

IRWD : 3.35 (-4.83%)
Ironwood: Q3 Earnings Snapshot

Ironwood: Q3 Earnings Snapshot

IRWD : 3.35 (-4.83%)
Ironwood: Q2 Earnings Snapshot

Ironwood: Q2 Earnings Snapshot

IRWD : 3.35 (-4.83%)
Down 7% in 2023, This Struggling Growth Stock Could Soon Make a Turnaround

Ironwood's plan to purchase a smaller biotech should address some issues that have shareholders concerned.

IRWD : 3.35 (-4.83%)
VECT : 16.85 (unch)
Why Ironwood Pharmaceuticals Stock Bumped Higher Today

Investors indicated approval of the company's upcoming $1 billion asset purchase.

ABBV : 172.38 (+2.75%)
IRWD : 3.35 (-4.83%)
VECT : 16.85 (unch)

Business Summary

Ironwood Pharmaceuticals, Inc. focuses on the development and commercialization of treatments primarily addressing gastrointestinal diseases. Linzess was launched in collaboration with Allergan for patients suffering from irritable bowel syndrome (IBS-C; 290 mcg) with constipation or chronic idiopathic...

See More

Key Turning Points

3rd Resistance Point 4.00
2nd Resistance Point 3.90
1st Resistance Point 3.71
Last Price 3.35
1st Support Level 3.42
2nd Support Level 3.32
3rd Support Level 3.13

See More

52-Week High 15.70
Fibonacci 61.8% 10.97
Fibonacci 50% 9.51
Fibonacci 38.2% 8.05
Last Price 3.35
52-Week Low 3.32

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar